Dysfunction of the Blood-Brain Barrier—A Key Step in Neurodegeneration and Dementia
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
The vascular endothelium in the brain is an essential part of the blood-brain-barrier (BBB) because of its very tight structure to secure a functional and molecular separation of the brain from the rest of the body and to protect neurons from pathogens and toxins. Impaired transport of metabolites across the BBB due to its increasing dysfunction affects brain health and cognitive functioning, thus providing a starting point of neurodegenerative diseases. The term “cerebral metabolic syndrome” is proposed to highlight the importance of lifestyle factors in neurodegeneration and to describe the impact of increasing BBB dysfunction on neurodegeneration and dementia, especially in elderly patients. If untreated, the cerebral metabolic syndrome may evolve into dementia. Due to the high energy demand of the brain, impaired glucose transport across the BBB via glucose transporters as GLUT1 renders the brain increasingly susceptible to neurodegeneration. Apoptotic processes are further supported by the lack of essential metabolites of the phosphocholine synthesis. In Alzheimer`s disease, inflammatory and infectious processes at the BBB increase the dysfunction and are might be pace-making events. At this point, the potentially highly relevant role of the thrombocytic amyloid precursor protein (APP) in endothelial inflammation of the BBB is discussed. Chronic inflammatory processes of the BBB transmitted to an increasing number of brain areas might cause a lasting build-up of spreading, pore-forming ß-amyloid fragments explaining the dramatic progression of the disease. In the view of the essential requirement of an early diagnosis to investigate and implement causal therapeutic strategies for against dementia, brain imaging methods are of great importance. Therefore, status and opportunities in the field of diagnostic imaging of the living human brain will be portrayed, comprising diverse techniques such as positron emissions tomography (PET) and functional magnetic resonance imaging (fMRI) to uncover the patterns of atrophy, protein deposits, hypometabolism, and molecular as well as functional alterations in Alzheimer`s disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Neuroinflammation in Alzheimer's disease
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226 · cited 2×
“Inflammation (Heneka et al., 2015) or infections (Holmes et al.”
BackgroundCardiovascular Morbidity and Mortality Associated With the Metabolic Syndrome
Isomaa, B., Almgren, P., Tuomi, T., Forsén, B., Lahti, K., Nissén, M., Taskinen, M.-R., & Groop, L. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.683 · Cited by 4,760 · cited 1×
“In the case of metabolic syndrome, hypertension is related to myocardial infarction and/or stroke (Isomaa et al., 2001), while impaired glucose tolerance is the prodromal stage of diabetes (Mendrick et al.”
BackgroundGlobal, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015
Roth, G. A., Johnson, C., Abajobir, A., Abd-Allah, F., Abera, S. F., Abyu, G., Ahmed, M., Aksut, B., Alam, T., Alam, K., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.04.052 · Cited by 3,791
Buckner, R. L., Sepulcre, J., Talukdar, T., Krienen, F. M., Liu, H., Hedden, T., Andrews-Hanna, J. R., Sperling, R. A., & Johnson, K. A. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.5062-08.2009 · Cited by 2,862
Changes in grey matter induced by training
Draganski, B., Gaser, C., Busch, V., Schuierer, G., Bogdahn, U., & May, A. (2004) · Nature · doi:10.1038/427311a · Cited by 2,373 · cited 1×
“…inflammation can be associated with various severe diseases with underlying factors ranging from a genetic disposition to immunological problems, there is no convincing explanation for the chronic inflammatory processes in dementia lasting for years (Dunn et al., 2005; Chitnis and Weiner, 2017).”
BackgroundAzevedo, F. A. C., Carvalho, L. R. B., Grinberg, L. T., Farfel, J. M., Ferretti, R. E. L., Leite, R. E. P., Filho, W. J., Lent, R., & Herculano‐Houzel, S. (2009) · Journal of Comparative Neurology · doi:10.1002/cne.21974 · Cited by 2,337
Sex and Gender Differences in Risk, Pathophysiology and Complications of Type 2 Diabetes Mellitus
Kautzky-Willer, A., Harreiter, J., & Pacini, G. (2016) · Endocrine Reviews · doi:10.1210/er.2015-1137 · Cited by 2,043
Dominy, S. S., Lynch, C., Ermini, F., Benedyk, M., Marczyk, A., Konradi, A., Nguyen, M., Haditsch, U., Raha, D., Griffin, C., et al. (2019) · Science Advances · doi:10.1126/sciadv.aau3333 · Cited by 1,966
Baumgart, M., Snyder, H. M., Carrillo, M. C., Fazio, S., Kim, H., & Johns, H. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.05.016 · Cited by 1,660
Sugar for the brain: the role of glucose in physiological and pathological brain function
Mergenthaler, P., Lindauer, U., Dienel, G. A., & Meisel, A. (2013) · Trends in Neurosciences · doi:10.1016/j.tins.2013.07.001 · Cited by 1,612
Alzheimer's disease: Targeting the Cholinergic System
H. Ferreira-Vieira, T., M. Guimaraes, I., R. Silva, F., & M. Ribeiro, F. (2016) · Current Neuropharmacology · doi:10.2174/1570159x13666150716165726 · Cited by 1,551
Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function
Arvanitakis, Z., Wilson, R. S., Bienias, J. L., Evans, D. A., & Bennett, D. A. (2004) · Archives of Neurology · doi:10.1001/archneur.61.5.661 · Cited by 1,258
Network Analysis of Intrinsic Functional Brain Connectivity in Alzheimer's Disease
Supekar, K., Menon, V., Rubin, D., Musen, M., & Greicius, M. D. (2008) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000100 · Cited by 1,148
O'Brien, J. T., & Thomas, A. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00463-8 · Cited by 1,136
Use of Florbetapir-PET for Imaging β-Amyloid Pathology
Clark, C. M. (2011) · JAMA · doi:10.1001/jama.2010.2008 · Cited by 1,117
Glucose transporters in the 21st Century
Thorens, B., & Mueckler, M. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00712.2009 · Cited by 1,013 · cited 1×
“Due to the steadily high demand for glucose, it is evolutionarily implicated that the glucose-transport into the brain—to a large extent—does not depend on the insulin system (Thorens and Mueckler, 2010), which is a signaling system that is directing blood glucose into tissues upon demand.”
BackgroundRole of Glutamate and NMDA Receptors in Alzheimer’s Disease
Wang, R., & Reddy, P. H. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160763 · Cited by 1,009
APP processing in Alzheimer’s disease.
Zhang, Y.-W., Thompson, R., Zhang, H., & Xu, H. (2011) · Molecular Brain · doi:10.1186/1756-6606-4-3 · Cited by 983
Sex modifies the APOE ‐related risk of developing Alzheimer disease
Altmann, A., Tian, L., Henderson, V. W., Greicius, M. D., & Alzheimer's Disease Neuroimaging Initiative Investigators (2014) · Annals of Neurology · doi:10.1002/ana.24135 · Cited by 891
Inflammatory processes in Alzheimer's disease
Heneka, M. T., & O'Banion, M. K. (2007) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.11.017 · Cited by 782
Astrocyte function from information processing to cognition and cognitive impairment
Santello, M., Toni, N., & Volterra, A. (2019) · Nature Neuroscience · doi:10.1038/s41593-018-0325-8 · Cited by 737
Mosconi, L., Tsui, W. H., Herholz, K., Pupi, A., Drzezga, A., Lucignani, G., Reiman, E. M., Holthoff, V., Kalbe, E., Sorbi, S., et al. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.045385 · Cited by 726 · cited 1×
“Particularly [18F]-FDG PET is a valuable diagnostic tool to optimize the early and differential diagnosis of various pathologies comprising dementia (Mosconi et al., 2008).”
MethodGLUT1 reductions exacerbate Alzheimer's disease vasculo-neuronal dysfunction and degeneration
Winkler, E. A., Nishida, Y., Sagare, A. P., Rege, S. V., Bell, R. D., Perlmutter, D., Sengillo, J. D., Hillman, S., Kong, P., Nelson, A. R., et al. (2015) · Nature Neuroscience · doi:10.1038/nn.3966 · Cited by 689
FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease
Foster, N. L., Heidebrink, J. L., Clark, C. M., Jagust, W. J., Arnold, S. E., Barbas, N. R., DeCarli, C. S., Scott Turner, R., Koeppe, R. A., Higdon, R., et al. (2007) · Brain · doi:10.1093/brain/awm177 · Cited by 608
Beginnings of a Good Apoptotic Meal: The Find-Me and Eat-Me Signaling Pathways
Ravichandran, K. S. (2011) · Immunity · doi:10.1016/j.immuni.2011.09.004 · Cited by 559
The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia
Iadecola, C. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0718-6 · Cited by 557 · cited 3×
“Overlaps between diverse forms of dementia may further complicate diagnostics (Iadecola, 2010).”
BackgroundInfluentialOn the path to 2025: understanding the Alzheimer’s disease continuum
Aisen, P. S., Cummings, J., Jack, C. R., Morris, J. C., Sperling, R., Frölich, L., Jones, R. W., Dowsett, S. A., Matthews, B. R., Raskin, J., et al. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0283-5 · Cited by 556
Blood lactate is an important energy source for the human brain.
van Hall, G., Stømstad, M., Rasmussen, P., Jans, Ø., Zaar, M., Gam, C., Quistorff, B., Secher, N. H., & Nielsen, H. B. (2009) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2009.35 · Cited by 522
Occurrence of T cells in the brain of Alzheimer's disease and other neurological diseases
Togo, T., Akiyama, H., Iseki, E., Kondo, H., Ikeda, K., Kato, M., Oda, T., Tsuchiya, K., & Kosaka, K. (2002) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(01)00496-9 · Cited by 481
Blood-Brain Barrier Dysfunction and the Pathogenesis of Alzheimer’s Disease
Yamazaki, Y., & Kanekiyo, T. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091965 · Cited by 451 · cited 2×
“In contrast to atherosclerosis and the related metabolic syndrome, the fundamental consequences of BBB impairment have only recently become the focus of broader attention (Noe, 2009; Yamazaki and Kanekiyo, 2017).”
BackgroundIntraneuronal β-amyloid accumulation and synapse pathology in Alzheimer’s disease
Gouras, G. K., Tampellini, D., Takahashi, R. H., & Capetillo-Zarate, E. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0679-9 · Cited by 372
Tzeng, N.-S., Chung, C.-H., Lin, F.-H., Chiang, C.-P., Yeh, C.-B., Huang, S.-Y., Lu, R.-B., Chang, H.-A., Kao, Y.-C., Yeh, H.-W., et al. (2018) · Neurotherapeutics · doi:10.1007/s13311-018-0611-x · Cited by 356
Review: Systemic inflammation andAlzheimer's disease
Holmes, C. (2013) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2012.01307.x · Cited by 356
Neuroinflammatory TNFα Impairs Memory via Astrocyte Signaling
Habbas, S., Santello, M., Becker, D., Stubbe, H., Zappia, G., Liaudet, N., Klaus, F. R., Kollias, G., Fontana, A., Pryce, C. R., et al. (2015) · Cell · doi:10.1016/j.cell.2015.11.023 · Cited by 347
Omega-3 Polyunsaturated Fatty Acids: Benefits and Endpoints in Sport
Gammone, M. A., Riccioni, G., Parrinello, G., & D’Orazio, N. (2018) · Nutrients · doi:10.3390/nu11010046 · Cited by 326 · cited 1×
“Beyond membrane stiffness and other factors, inflammation easily adds to the concept of BBB dysfunction as a key factor to transform a cerebral metabolic syndrome into neurodegeneration (Heneka and O’Banion, 2007; Bennani-Baiti et al., 2015; Heneka et al., 2015; Gleizes et al., 2016).”
BackgroundAmyloid vs FDG-PET in the differential diagnosis of AD and FTLD
Rabinovici, G. D., Rosen, H. J., Alkalay, A., Kornak, J., Furst, A. J., Agarwal, N., Mormino, E. C., O'Neil, J. P., Janabi, M., Karydas, A., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31823b9c5e · Cited by 318
Brain levels of sex steroid hormones in men and women during normal aging and in Alzheimer's disease
Rosario, E. R., Chang, L., Head, E. H., Stanczyk, F. Z., & Pike, C. J. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.04.008 · Cited by 289
The role of Aβ42 in Alzheimer's disease
Younkin, S. G. (1998) · Journal of Physiology-Paris · doi:10.1016/s0928-4257(98)80035-1 · Cited by 282 · cited 1×
“There has been extensive work to investigate how Aβ42 exerts its toxic function (Younkin, 1998).”
BackgroundReview and Meta-Analysis of Biomarkers and Diagnostic Imaging in Alzheimer's Disease
Bloudek, L. M., Spackman, D. E., Blankenburg, M., & Sullivan, S. D. (2011) · Journal of Alzheimer’s Disease · doi:10.3233/jad-2011-110458 · Cited by 282
Iyo, M., Namba, H., Fukushi, K., Shinotoh, H., Nagatsuka, S., Suhara, T., Sudo, Y., Suzuki, K., & Irie, T. (1997) · The Lancet · doi:10.1016/s0140-6736(96)09124-6 · Cited by 259
Glucose Transporters in Brain: In Health and in Alzheimer’s Disease
Szablewski, L. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-160841 · Cited by 211 · cited 1×
“This finding is crucial for and consistent with increasingly upcoming hypotheses, relating dementia to metabolic dysfunction or energy deficits of the brain (Jurcovicova, 2014; Szablewski, 2017).”
ResultPrion-like Properties of Tau Protein: The Importance of Extracellular Tau as a Therapeutic Target
Holmes, B. B., & Diamond, M. I. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.r114.549295 · Cited by 202 · cited 1×
“, 1992) and tau protein (Holmes and Diamond, 2014; Stancu et al., 2019) seem to play a crucial role.”
BackgroundPharmacological drug treatment of Alzheimer disease: The cholinergic hypothesis revisited
Ladner, C. J., & Lee, J. M. (1998) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199808000-00001 · Cited by 142 · cited 2×
“Therefore, the therapy of AD includes the administration of acetylcholinesterase inhibitors (Ladner and Lee, 1998), substances that are meant to prevent the breakdown of acetylcholine.”
BackgroundBennani-Baiti, B., Toegel, S., Viernstein, H., Urban, E., Noe, C. R., & Bennani-Baiti, I. M. (2015) · PLOS ONE · doi:10.1371/journal.pone.0139101 · Cited by 20
Self-citation
Cited by
Mou, Y., Du, Y., Zhou, L., Yue, J., Hu, X., Liu, Y., Chen, S., Lin, X., Zhang, G., Xiao, H., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.796288 · Cited by 432
Munawara, U., Catanzaro, M., Xu, W., Tan, C., Hirokawa, K., Bosco, N., Dumoulin, D., Khalil, A., Larbi, A., Lévesque, S., et al. (2021) · Immunity & Ageing · doi:10.1186/s12979-021-00236-x · Cited by 74
iPSC-derived PSEN2 (N141I) astrocytes and microglia exhibit a primed inflammatory phenotype
Sullivan, M. A., Lane, S. D., McKenzie, A. D. J., Ball, S. R., Sunde, M., Neely, G. G., Moreno, C. L., Maximova, A., Werry, E. L., & Kassiou, M. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02951-2 · Cited by 23
Metadata
- Authors
- Noe, C. R., Noe-Letschnig, M., Handschuh, P., Noe, C. A., & Lanzenberger, R.
- Venue
- Frontiers in Aging Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2020-07-24
- Volume
- 12
- Pages
- 185-185
- ISSN
- 1663-4365 (ISSN-L)
- OpenAlex
- W3045264879
- Cited by
- 73
- References
- 45
- FWCI
- 3.52
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.